MarketCap
Halozyme Therapeutics HALO
$ 80.84
3.88%
Facebook
X
Telegram
Halozyme Therapeutics Financial Ratios 2025-2008 | HALO
Brief overview of Halozyme Therapeutics's multiples and efficiency
Ratios are assessed across five available annual reports in the 2021–2025 interval.
The latest available valuation ratios are P/E 30.47x (median 16.86x), EV/EBITDA 24.98x (median 18.01x), P/S 6.91x (median 7.23x). The current ratio basket stands about 38.7% above the five-year base, increasing sensitivity to weak reports.
At the current P/E, inverse earnings yield is 3.3%, a useful bridge between price and business earnings.
Current measures of operating quality are ROE 6.5%, ROA 12.5%, ROCE 9.6%. Business quality is below comfortable levels on current returns. Better margins or turnover are needed.
Current PEG of 0.87x shows no clear imbalance between price and expected earnings momentum.
The time from paying for inputs to receiving cash rose from 289.5 days to 322.5 days. Cash turnover slowed.
Valuation takeaway
Halozyme Therapeutics combines weak profitability with valuation above its historical norm, leaving limited cushion.
Annual Financial Ratios Halozyme Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
30.5 | 16.5 | 16.9 | 33.8 | 12.4 | 47.7 | -38.8 | -28.6 | 41.6 | -13.9 | -34.6 | -25.6 | -21.6 | -14.7 | -55.1 | -13.4 | - | - |
P/S |
6.9 | 7.2 | 5.7 | 10.4 | 11.3 | 23.0 | 14.3 | 15.1 | 8.3 | 9.8 | 8.3 | 23.3 | 32.9 | 18.6 | 19.4 | 52.3 | - | - |
EPS |
2.6 | 3.5 | 2.1 | 1.5 | 2.9 | 0.9 | -0.5 | -0.6 | 0.5 | -0.8 | -0.2 | -0.6 | -0.7 | -0.5 | -0.2 | -0.6 | -0.7 | - |
EV (Enterprise Value) |
12 B | 8.93 B | 6.28 B | 8.28 B | 4.87 B | 6.02 B | 3.16 B | 2.43 B | 2.76 B | 1.66 B | 1.21 B | 1.82 B | 1.89 B | 774 M | 1.09 B | 630 M | -67.5 M | -63.7 M |
EBITDA per Share |
4.01 | 4.43 | 2.64 | 2 | 1.98 | 1.08 | -0.44 | -0.466 | 0.61 | -0.631 | -0.203 | -0.499 | -0.702 | -0.473 | -0.183 | -0.52 | - | - |
EV/EBITDA |
25.0 | 15.9 | 18.0 | 30.2 | 17.2 | 48.0 | -48.6 | -35.3 | 31.9 | -19.6 | -43.5 | -28.4 | -23.0 | -13.7 | -55.4 | -12.0 | 1.2 | - |
PEG |
0.87 | -0.51 | -0.36 | -0.38 | -0.1 | -0.46 | 3.62 | 0.13 | -0.27 | -0.06 | 0.62 | 1.05 | -0.4 | -0.1 | 0.83 | - | - | - |
P/B |
197.8 | 20.2 | 56.7 | 40.3 | 4.5 | 10.6 | 30.6 | 9.2 | 12.6 | -44.2 | 25.9 | 42.4 | -90.1 | 16.1 | 100.0 | 7.8 | - | - |
P/CF |
14.8 | 15.3 | 12.2 | 28.5 | 16.7 | 111.1 | -31.3 | -42.4 | 19.8 | -26.9 | -28.3 | -35.8 | -34.9 | -12.0 | -31.0 | -15.7 | - | - |
ROE % |
649.18 | 122.06 | 336.00 | 119.04 | 204.47 | 85.46 | -78.72 | -32.28 | 30.22 | 317.18 | -74.96 | -165.35 | 417.59 | -109.62 | -181.37 | -261.61 | -845.39 | - |
ROA % |
12.55 | 21.52 | 16.25 | 10.98 | 36.46 | 22.26 | -12.77 | -18.25 | 12.11 | -39.39 | -17.73 | -41.20 | -82.01 | -39.75 | -30.06 | -58.29 | - | - |
ROCE % |
960.80 | 151.58 | 402.79 | 157.56 | 140.09 | 95.50 | -14.08 | -23.83 | 20.84 | -40.21 | -23.00 | -44.50 | -105.36 | -46.32 | -40.94 | -266.60 | -846.81 | - |
Current Ratio |
1.0 | 1.2 | 1.1 | 1.1 | - | - | 6.3 | 2.9 | 3.9 | 4.7 | 2.8 | 6.6 | 3.7 | 6.9 | 3.7 | - | - | - |
DSO |
93.4 | 93.7 | 102.2 | 63.9 | 40.2 | 107.2 | 110.7 | 72.1 | 25.5 | 39.0 | 87.6 | 44.3 | 60.6 | 135.4 | 14.7 | 31.2 | - | - |
DIO |
253.9 | 308.5 | 216.1 | 201.8 | 257.0 | 379.2 | 235.3 | 814.7 | 60.3 | 160.7 | 118.4 | 102.9 | 360.6 | 890.7 | 803.0 | - | - | - |
DPO |
24.8 | 25.3 | 28.0 | 25.2 | 7.8 | 35.2 | 51.6 | 146.9 | 93.1 | 39.3 | 56.2 | 48.2 | 183.2 | 757.6 | 10697.8 | - | - | - |
Operating Cycle |
347.3 | 402.2 | 318.2 | 265.7 | 297.2 | 486.4 | 346.0 | 886.8 | 85.8 | 199.8 | 206.0 | 147.2 | 421.2 | 1026.1 | 817.8 | 31.2 | - | - |
Cash Conversion Cycle |
322.5 | 376.9 | 290.2 | 240.5 | 289.5 | 451.2 | 294.4 | 740.0 | -7.3 | 160.4 | 149.9 | 99.0 | 238.0 | 268.5 | -9880.0 | 31.2 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Halozyme Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
1.27 | 1.49 | 1.36 | 0.96 | - | 1.08 | 0.73 | 0.61 | - | 0.62 | 0.57 | 0.29 | - | 0.45 | 0.16 | 0.44 | - | 1.53 | 0.64 | 0.2 | 0.54 | 0.27 | 0.19 | -0.04 | -0.24 | -0.17 | -0.1 | 0.01 | -0.01 | -0.19 | -0.16 | -0.19 | 870 | 20 | -230 | -260 | 0.03 | -0.23 | -0.21 | -0.16 | 0.03 | -0.19 | 0.02 | -0.12 | -0.04 | -0.16 | -0.13 | -0.22 | -0.19 | -0.17 | -0.2 | -0.17 | -0.04 | -0.18 | -0.13 | -0.14 | -0.18 | 0.05 | 0.03 | -0.1 |
EBITDA per Share |
1.6 | 1.88 | 1.69 | 1.17 | - | 1.31 | 0.94 | 0.77 | - | 0.69 | 0.74 | 0.42 | - | 0.62 | 0.25 | 0.56 | - | 0.54 | 0.66 | 0.37 | - | 0.3 | 0.22 | -0.02 | - | -0.16 | -0.09 | 0.03 | - | -0.17 | -0.14 | -0.16 | - | 0.06 | -0.19 | -0.21 | - | -0.17 | -0.17 | -0.12 | - | -0.17 | 0.04 | -0.11 | - | -0.14 | -0.11 | -0.21 | - | -0.16 | -0.19 | -0.16 | - | -0.17 | -0.12 | -0.14 | - | 0.06 | 0.04 | -0.09 |
ROE % |
177.21 | 139.16 | 136.61 | 130.18 | 105.69 | 138.53 | 157.76 | 185.70 | 142.50 | 206.04 | 180.94 | 154.54 | 94.38 | 171.27 | 184.10 | 217.63 | 194.54 | 242.97 | 190.05 | 130.77 | 85.46 | -0.46 | -51.69 | -84.72 | -78.72 | -42.09 | -26.02 | -19.28 | -32.28 | 28.03 | 40.54 | 34.98 | 30.22 | 55.08 | 142.88 | 240.38 | 317.18 | 169.18 | 12.74 | -132.50 | -239.59 | -188.66 | -170.38 | -147.23 | -165.35 | -42.61 | 102.94 | 256.91 | 417.60 | 298.60 | 161.14 | 17.82 | -109.62 | -269.53 | -181.20 | -123.91 | -181.36 | 47.39 | 28.59 | -88.40 |
ROA % |
26.92 | 27.78 | 24.62 | 20.75 | 15.38 | 19.70 | 17.36 | 14.96 | 10.78 | 14.09 | 11.04 | 12.08 | 9.75 | 28.02 | 33.63 | 35.24 | 30.07 | 42.69 | 30.66 | 26.20 | 22.26 | 3.56 | -7.10 | -14.14 | -12.77 | -7.17 | -9.08 | -11.69 | -18.25 | 6.06 | 12.92 | 12.20 | 12.11 | -22.19 | -33.78 | -38.14 | -39.39 | -43.99 | -48.84 | -53.35 | -56.67 | -44.78 | -41.08 | -36.10 | -41.20 | -59.62 | -66.35 | -79.05 | -82.01 | -63.68 | -59.58 | -47.48 | -39.75 | -64.48 | -41.78 | -26.63 | -30.06 | 7.85 | 4.74 | -14.65 |
ROCE % |
217.44 | 169.48 | 166.74 | 159.64 | 130.29 | 165.72 | 192.21 | 233.41 | 179.67 | 265.55 | 241.74 | 208.27 | 126.57 | 153.40 | 145.23 | 208.67 | 179.59 | 206.27 | 199.01 | 119.17 | 44.11 | 17.37 | -24.54 | -40.87 | -38.74 | -48.97 | -30.30 | -24.60 | -27.83 | -23.95 | -25.94 | -31.09 | -21.56 | 48.46 | 111.46 | 173.47 | 186.68 | 132.64 | 72.46 | -26.77 | -76.55 | -122.56 | -104.65 | -175.48 | -143.12 | -50.61 | 106.06 | 234.71 | 295.70 | 254.70 | 133.43 | -8.23 | -100.75 | -53.47 | 15.93 | -43.93 | -12.94 | 47.27 | 28.40 | -88.62 |
Current Ratio |
1.1 | 1.3 | 1.2 | 1.3 | 1.2 | 1.3 | 1.2 | 1.1 | 1.1 | 1.1 | 1.1 | 1.0 | 1.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
97.1 | 84.8 | 86.7 | 102.0 | - | 76.0 | 78.0 | 97.5 | - | 92.0 | 86.0 | 107.5 | - | 92.3 | 90.8 | 79.7 | - | 104.5 | 80.8 | 95.4 | 73.3 | 136.5 | 161.5 | 282.8 | 101.1 | 117.3 | 138.6 | 71.7 | 45.5 | 107.1 | 77.8 | 77.0 | 10.7 | 31.7 | 59.8 | 58.4 | 36.7 | 44.9 | 42.9 | 51.6 | 75.8 | 142.3 | 68.2 | 101.6 | 27.5 | 57.2 | 45.4 | 69.6 | 66.4 | 51.8 | 57.4 | 95.6 | 65.8 | 268.6 | 184.7 | 110.2 | 85.6 | 9.0 | 8.9 | - |
DIO |
196.5 | 303.4 | 340.9 | 289.1 | - | 268.4 | 377.7 | 476.9 | - | 217.5 | 218.6 | 269.4 | - | 193.7 | 195.4 | 291.3 | - | 281.1 | 231.7 | 298.2 | - | 995.5 | 965.7 | 710.4 | - | 120.0 | 1427.3 | 510.2 | - | 3298.0 | 2469.5 | 415.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
17.0 | 28.1 | 38.1 | 28.6 | - | 25.7 | 33.1 | 40.5 | - | 24.5 | 17.1 | 34.2 | - | 29.3 | 18.1 | 8.0 | - | 19.4 | 10.1 | 6.2 | - | 31.6 | 30.6 | 65.9 | - | 26.3 | 312.8 | 103.2 | - | 594.6 | 445.2 | 179.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 388.2 | 427.6 | 391.1 | - | 344.4 | 455.7 | 574.4 | - | 309.5 | 304.6 | 376.8 | - | 286.0 | 286.2 | 371.0 | - | 385.6 | 312.5 | 393.6 | 73.3 | 1132.1 | 1127.2 | 993.2 | 101.1 | 237.3 | 1565.8 | 581.8 | 45.5 | 3405.1 | 2547.3 | 492.2 | 10.7 | 31.7 | 59.8 | 58.4 | 36.7 | 44.9 | 42.9 | 51.6 | 75.8 | 142.3 | 68.2 | 101.6 | 27.5 | 57.2 | 45.4 | 69.6 | 66.4 | 51.8 | 57.4 | 95.6 | 65.8 | 268.6 | 184.7 | 110.2 | 85.6 | 9.0 | 8.9 | - |
Cash Conversion Cycle |
- | 360.1 | 389.5 | 362.6 | - | 318.7 | 422.6 | 534.0 | - | 285.0 | 287.5 | 342.6 | - | 256.7 | 268.0 | 362.9 | - | 366.3 | 302.4 | 387.4 | 73.3 | 1100.5 | 1096.5 | 927.3 | 101.1 | 211.0 | 1253.0 | 478.7 | 45.5 | 2810.5 | 2102.1 | 312.4 | 10.7 | 31.7 | 59.8 | 58.4 | 36.7 | 44.9 | 42.9 | 51.6 | 75.8 | 142.3 | 68.2 | 101.6 | 27.5 | 57.2 | 45.4 | 69.6 | 66.4 | 51.8 | 57.4 | 95.6 | 65.8 | 268.6 | 184.7 | 110.2 | 85.6 | 9.0 | 8.9 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Halozyme Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Irlanda
